Cost-effectiveness of apixaban versus other oral anticoagulants and aspirin for stroke prevention in atrial fibrillation in indian subcontinent

被引：1
|
作者：
Kulkarni, N. [1 ]
Taur, S. [1 ]
Tichy, E. [2 ]
Kongnakorn, T. [3 ]
Sharma, R. [4 ]
机构：
[1] Pfizer India, Med Affairs, Mumbai, Maharashtra, India
[2] Evidera, Budapest, Hungary
[3] Evidera, London, England
[4] Fortis Hosp, Mohali, India
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷
关键词：
D O I：
10.1093/eurheartj/ehab849.022
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
    Marchetti, M.
    Liberato, N. L.
    Rognoni, C.
    Quaglini, S.
    HAEMATOLOGICA, 2014, 99 : 487 - 487
  • [32] COST-EFFECTIVENESS OF APIXABAN VERSUS STANDARD OF CARE FOR THE PREVENTION OF STROKE: AN ANALYSIS OF PATIENTS WITH ATRIAL FIBRILLATION IN GRECE
    Athanasakis, K.
    Arzoumanidou, D.
    Karampli, E.
    Armelidou, E.
    Giovas, P.
    Petrikkou, E.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2013, 16 (07) : A524 - A525
  • [33] Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
    Hallinen, Taru
    Soini, Erkki
    Asseburg, Christian
    Linna, Miika
    Eloranta, Pia
    Sintonen, Sari
    Kosunen, Mikko
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 745 - 755
  • [34] Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban
    Tatjana S. Potpara
    Marija M. Polovina
    Marina M. Licina
    Radan M. Stojanovic
    Milica S. Prostran
    Gregory Y. H. Lip
    Advances in Therapy, 2012, 29 : 491 - 507
  • [35] Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban
    Potpara, Tatjana S.
    Polovina, Marija M.
    Licina, Marina M.
    Stojanovic, Radan M.
    Prostran, Milica S.
    Lip, Gregory Y. H.
    ADVANCES IN THERAPY, 2012, 29 (06) : 491 - 507
  • [36] Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting
    Athanasakis, Kostas
    Karampli, Eleftheria
    Tsounis, Dimitrios
    Bilitou, Aikaterini
    Kyriopoulos, John
    CLINICAL DRUG INVESTIGATION, 2015, 35 (11) : 693 - 705
  • [37] Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation
    Canestaro, William J.
    Patrick, Amanda R.
    Avorn, Jerry
    Ito, Kouta
    Matlin, Olga S.
    Brennan, Troyen A.
    Shrank, William H.
    Choudhry, Niteesh K.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2013, 6 (06): : 724 - +
  • [38] Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting
    Kostas Athanasakis
    Eleftheria Karampli
    Dimitrios Tsounis
    Aikaterini Bilitou
    John Kyriopoulos
    Clinical Drug Investigation, 2015, 35 : 693 - 705
  • [39] Erratum to: Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
    Thitima Kongnakorn
    Tereza Lanitis
    Lieven Annemans
    Vincent Thijs
    Sophie Marbaix
    Clinical Drug Investigation, 2014, 34 : 753 - 753
  • [40] Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants
    Charalampos Kasmeridis
    Stavros Apostolakis
    Lars Ehlers
    Lars H. Rasmussen
    Giuseppe Boriani
    Gregory Y. H. Lip
    PharmacoEconomics, 2013, 31 : 971 - 980
12345